Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-CD371/CLEC12A Antibody (R3Y15)

Catalog #:   RHJ95302 Specific References (32) DATASHEET
Host species: Mouse
Isotype: IgG2a
Applications: ELISA, FCM, IF, WB
Accession: Q5QGZ9
Overview

Catalog No.

RHJ95302

Species reactivity

Human

Host species

Mouse

Isotype

IgG2a

Clonality

Monoclonal

Tested applications

ELISA: 1:10000, FCM: 1:200-1:400, IF: 1:200-1:500, WB: 1:500-1:2000

Target

CLEC12A, DCAL2, Dendritic cell-associated lectin 2, CLL-1, Myeloid inhibitory C-type lectin-like receptor, C-type lectin domain family 12 member A, CLL1, DCAL-2, C-type lectin-like molecule 1, MICL, CD371

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q5QGZ9

Applications

ELISA, FCM, IF, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% Sodium Azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

R3Y15

Data Image
  • Flow Cytometry
    Flow cytometric analysis of HL-60 cells using CLL1 mouse mAb (green) and negative control (red).
  • Immunofluorescence
    Immunofluorescence analysis of Hela cells using CLL1 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin.
References

CLEC12A-directed immunocytokine with target cell-restricted IL-15 activity for treatment of acute myeloid leukemia., PMID:40213559

28-color single tube for flow cytometric assessment of myeloid maturation, myeloid neoplasia, and acute myeloid leukemia minimal/measurable residual disease., PMID:40134341

A review of antibody-based immunotherapy clinical trials for adult acute myeloid leukemia (AML): monoclonal antibodies (mAbs) and beyond., PMID:40069930

Recognition and control of neutrophil extracellular trap formation by MICL., PMID:39143217

Crystal structure of the complex of CLEC12A and an antibody that interferes with binding of diverse ligands., PMID:38386511

Twenty-four-color full spectrum flow cytometry panel for minimal residual disease detection in acute myeloid leukemia., PMID:37533738

Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells., PMID:36563336

A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL., PMID:35288466

Regulation of the Expression, Oligomerisation and Signaling of the Inhibitory Receptor CLEC12A by Cysteine Residues in the Stalk Region., PMID:34638548

Anti-CD19 CAR T Cells That Secrete a Biparatopic Anti-CLEC12A Bridging Protein Have Potent Activity Against Highly Aggressive Acute Myeloid Leukemia In Vitro and In Vivo., PMID:34253594

Expression of the myeloid inhibitory receptor CLEC12A correlates with disease activity and cytokines in early rheumatoid arthritis., PMID:34045571

A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia., PMID:33617672

Exploring blast composition in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: CD45RA and CD371 improve diagnostic value of flow cytometry through assessment of myeloblast heterogeneity and stem cell aberrancy., PMID:33369070

Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes., PMID:33220589

A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells., PMID:33097838

Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML., PMID:33085758

Reduced polyfunctional T cells and increased cellular activation markers in adult allergy patients reporting adverse reactions to food., PMID:32698761

Chikungunya Virus Evades Antiviral CD8+ T Cell Responses To Establish Persistent Infection in Joint-Associated Tissues., PMID:32102875

Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity., PMID:31674143

MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis., PMID:31286786

Targeting CLL-1 for acute myeloid leukemia therapy., PMID:31014360

Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia., PMID:30401586

Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia., PMID:30183491

CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia., PMID:30037800

An Anti-CLL-1 Antibody-Drug Conjugate for the Treatment of Acute Myeloid Leukemia., PMID:29959143

Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia., PMID:29077054

Expression profile of novel cell surface molecules on different subsets of human peripheral blood antigen-presenting cells., PMID:27766148

MICL controls inflammation in rheumatoid arthritis., PMID:26275430

Modulation of monosodium urate crystal-induced responses in neutrophils by the myeloid inhibitory C-type lectin-like receptor: potential therapeutic implications., PMID:23837669

The C-type lectin Clec12A present on mouse and human dendritic cells can serve as a target for antigen delivery and enhancement of antibody responses., PMID:19494282

The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells., PMID:17609428

Human MICL (CLEC12A) is differentially glycosylated and is down-regulated following cellular activation., PMID:16838277

Datasheet
$ 220
Product specifications
50 μg 220 100 μg 350

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-CD371/CLEC12A Antibody (R3Y15) [RHJ95302]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only